Cancer discovery

First mRNA Cancer Vaccine Shows Success in Final Phase Trial

Updated

Abstract

Adding the mRNA-based vaccine intismeran autogene to pembrolizumab reduced the risk of disease recurrence or death by 42% in melanoma patients.

  • The trial was a phase III study named INTerpath-0001.
  • The combination treatment was administered following surgery for melanoma.
  • Results indicate a significant reduction in the risk of melanoma recurrence or mortality.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free